In this multi-institutional retrospective study, we analyzed the characteristics and outcomes of 118 patients with solitary bone plasmacytoma (SBP) and 57 with extramedullary plasmacytoma (SEP) diagnosed over 30 years. We also evaluated the impact of systemic therapy (ST), which is not routinely recommended, compared to standard radiation therapy (RT). The median age was 62 years (range: 17–85). Treatment

Journal of Hematology & Oncology (2025) 18:56 https://doi.org/10.1186/s13045-025-01713-2 The original article has been corrected to restore co-authors Yi Su, Ling Qiu, and Fang-yi Fan (lead contact) to co-Corresponding Authorship which was mistakenly removed by the production team which handled this article.Author notes Hao Yao, Shi-hui Ren, Lin-hui Wang and Ming-qiang Ren contributed equally to this

In the post-pandemic years, SARS-CoV-2 morbidity and mortality declined due to less pathogenic variants, active and passive immunization, and antiviral therapies. However, patients with hematological malignancies and/or undergoing hematopoietic cell transplantation (HCT) remain at increased risk for poor outcomes. Therefore, adherence to contact and droplet precautions is essential to avoid transmission

The coronavirus disease 2019 (COVID‐19) pandemic created major challenges for allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Scientific societies and authorities recommended cryopreserving grafts before starting conditioning regimens, despite limited data on the clinical impact. The Italian Group for Bone Marrow Transplantation (GITMO) conducted a registry‐based study involving 3492

B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell therapy has significantly improved survival outcomes in patients with relapsed or refractory multiple myeloma (RRMM), achieving unprecedented depth of response compared to conventional salvage regimens [1-3]. Minimal residual disease (MRD) negativity has emerged as a strong predictor of favorable prognosis in this setting [4] and

According to the European LeukemiaNet (ELN) 2022 classification, acute myeloid leukemia (AML) patients with intermediate or adverse risk are offered allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in first remission. In this EBMT study, we included 1735 adult AML patients with ELN‐2022 adverse‐risk cytogenetics allografted between 2010 and 2022 in first remission (67% de novo AML, median

Papillary renal cell carcinoma (pRCC), a main pathological subtype of non-clear cell RCC (nccRCC), has strong heterogeneity. Comparing to other nccRCC subtypes, advanced pRCC has the poorest prognosis. Due to its lower incidence compared to ccRCC, clinical research and exploration of non-invasive biomarkers for pRCC are limited, and it is often misclassified. Herein, we leveraged the advantages of

Conflicts of Interest The authors declare no conflicts of interest.

Not available.

Infections are a significant cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), with respiratory tract infections being predominant. This study evaluated the incidence of chronic lung diseases (asthma, COPD, and bronchiectasis) among 4,532 patients with CLL and their association with infection complications and outcomes. We found that bronchiectasis (5%), asthma (12.2%), and COPD

Not available.

Not available.

Not available.

Not available.

CAR T expansion has been linked to anti-tumor response in relapsed/refractory large B-cell lymphoma both in clinical trials and smaller real-world studies. Here, we present the largest multicenter real-world analysis to date, evaluating 262 patients treated with tisagenlecleucel or axicabtagene ciloleucel in second or subsequent relapse. Our findings underscore the complementary roles of multiparameter

Not available.

Multiple myeloma (MM) shows inherent clinical and biological heterogeneity, leading to variable treatment responses and outcomes. The complex molecular landscape of MM makes precise risk stratification through clinical genetic testing difficult. Thus, identifying better biomarkers is essential to enhance existing stratification methods and guide personalized therapy decisions. Here, we systematically

Not available.

Hematopoietic stem cell transplantation is a well-established treatment option for acquired aplastic anemia. Historically, upfront hematopoietic stem cell transplantation (HCT) with HLA-matched sibling donors is used in young patients and immunosuppressive therapy (IST) is used for all others. Over time, innovations in the transplant platform have decreased unwanted complications such as graft versus

We hypothesized that mean corpuscular hemoglobin (MCH) modulates the distribution of fetal hemoglobin (HbF) among F-cells in sickle cell disease, and mathematically modeled a hypothetical HbF distribution among F-cells following gene therapy or during highly successful hydroxyurea (HU) treatment. HbF, the prime genetic modulator of the phenotype of sickle cell disease, is largely excluded from the

The spatial proteomic profiling of complex tissues is essential for investigating cellular function in physiological and pathological states. However, the imbalance among resolution, protein coverage, and expense precludes their systematic application to analyze whole tissue sections in an unbiased manner and with high resolution. Here, we introduce panoramic spatial enhanced resolution proteomics

Conflicts of Interest The authors declare no conflicts of interest.

Although second allogeneic hematopoietic cell transplantation HCT (HCT2) is a potentially curative treatment for patients relapsing after their first HCT (HCT1), it is associated with higher non‐relapse mortality (NRM) compared with HCT1. Furthermore, while reduced‐intensity conditioning (RIC) in HCT2 might decrease NRM, there is no consensus on which patients may benefit from RIC. We retrospectively

The continuous improvement in progression-free survival (PFS) of multiple myeloma (MM) patients raises interest in evaluating peripheral residual disease (PRD) towards more frequent readouts of tumor kinetics while preserving quality of life. Here we present BloodFlow, a new method that combines immunomagnetic enrichment of CD138+ circulating plasma cells in peripheral blood (PB) with next-generation

The majority of calreticulin (CALR) mutations in myeloproliferative neoplasms (MPNs) are classified as either type 1, a 52 base-pair deletion (CALRdel52), or type 2, a 5 base-pair insertion (CALRins5). Both are gain-of-function (GOF) mutations that generate an identical mutant C-terminal tail, which mediates the binding to and activation of the thrombopoietin receptor MPL. We recently reported that

Suppression of plasminogen activation and/or plasmin activity (PA) reduces blood loss and decreases hemorrhage-related death. However, whether the endogenous PA system is a biological mechanism to prevent intravascular thrombus formation is debated, and the potential that reduced PA may increase venous thrombosis/thromboembolism (VTE) risk cautions against the use of antifibrinolytic agents. We aimed

Early recognition and treatment of heparin-induced thrombocytopenia (HIT) are crucial to prevent severe complications. While immunoassays offer rapid diagnosis, their sensitivity and specificity are suboptimal. Sequential combinations of quantitative immunoassay results improve their diagnostic accuracy. We aimed to validate two Bayesian approaches combining two rapid immunoassays and to compare their

Long noncoding RNAs (lncRNAs) are a significant yet largely uncharted component of the cancer transcriptome, with their isoform-specific functions remaining poorly understood. In this study, we employed RNA-targeting CRISPR-Cas13d to uncover and characterize hundreds of tumor-essential (te)-lncRNA isoforms with clinical relevance. Focusing on multiple myeloma (MM), we targeted the lncRNA transcriptome

The autoimmune response driving hematopoietic stem and progenitor cell (HSPC) destruction in immune-mediated aplastic anemia (AA) remains incompletely understood. We previously identified a disease-specific immune cell network involving T-, B-, and myeloid cells. However, the interactions within this network, the interaction with the microenvironment and the chronological events in AA development,

Outcomes in patients with relapsed/refractory (RR) AML are poor. We sought to investigate if CPX‐531 in combination with venetoclax (CPX + VEN) was tolerable and effective in RR AML. This was a single institution phase 1b/2 trial of CPX + VEN. Patients aged ≥ 18 years with RR AML who were fit for intensive chemotherapy were eligible. Prior venetoclax exposure was allowed. The phase 1b portion followed